Alveolar bone is a mechanosensitive tissue that provides structural support for teeth. Alveolar bone loss is common with aging, menopause, tooth loss, and periodontitis and can lead to additional tooth loss, reduced denture fixation, and challenges in placing dental implants. The current studies suggest that sclerostin and DKK1, which are established osteocyte-derived inhibitors of bone formation, contribute to alveolar bone loss associated with estrogen ablation and edentulism in rats. Estrogen-deficient ovariectomized rats showed significant mandibular bone loss that was reversed by systemic administration of sclerostin antibody (SAB) alone and in combination with DKK1 antibody (DAB). Osteocytes in the dentate and edentulous rat maxilla expressed Sost (sclerostin) and Dkk1 (DKK1) mRNA, and molar extraction appeared to acutely increase DKK1 expression. In a chronic rat maxillary molar extraction model, systemic SAB administration augmented the volume and height of atrophic alveolar ridges, effects that were enhanced by coadministering DAB. SAB and SAB+DAB also fully reversed bone loss that developed in the opposing mandible as a result of hypo-occlusion. In both treatment studies, alveolar bone augmentation with SAB or SAB+DAB was accompanied by increased bone mass in the postcranial skeleton. Jaw bone biomechanics showed that intact sclerostin-deficient mice exhibited stronger and denser mandibles as compared with wild-type controls. These studies show that sclerostin inhibition, with and without DKK1 coinhibition, augmented alveolar bone volume and architecture in rats with alveolar bone loss. These noninvasive approaches may have utility for the conservative augmentation of alveolar bone.
AgholmeFIsakssonHKuhstossSAspenbergP.2011. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone. 48(5):988–996.
2.
AgholmeFLiXIsakssonHKeHZAspenbergP.2010. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 25(11):2412–2418.
3.
AroHTAlmJJMoritzNMakinenTJLankinenP.2012. Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop. 83(2):107–114.
4.
BalemansWEbelingMPatelNVan HulEOlsonPDioszegiMLaczaCWuytsWVan Den EndeJWillemsPet al. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 10(5):537–543.
5.
BashutskiJDEberRMKinneyJSBenavidesEMaitraSBraunTMGiannobileWVMcCauleyLK. 2010. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 363(25):2396–2405.
6.
BoydenLMMaoJBelskyJMitznerLFarhiAMitnickMAWuDInsognaKLiftonRP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 346(20):1513–1521.
7.
CarreiraACLojudiceFHHalcsikENavarroRDSogayarMCGranjeiroJM. 2014. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res. 93(4):335–345.
8.
ChenHXuXLiuMZhangWKeHZQinATangTLuE.2015. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 76:141–148.
9.
CosmanFCrittendenDBAdachiJDBinkleyNCzerwinskiEFerrariSHofbauerLCLauELewieckiEMMiyauchiAet al. 2016. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 375(16):1532–1543.
10.
EspositoMGrusovinMGKwanSWorthingtonHVCoulthardP.2008. Interventions for replacing missing teeth: bone augmentation techniques for dental implant treatment. Cochrane Database Syst Rev. (3):CD003607.
11.
FlorioMGunasekaranKStolinaMLiXLiuLTiptonBSalimi-MoosaviHAsuncionFJLiCSunBet al. 2016. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 7:11505.
12.
GardnerJCvan BezooijenRLMervisBHamdyNALowikCWHamersmaHBeightonPPapapoulosSE. 2005. Bone mineral density in sclerosteosis: affected individuals and gene carriers. J Clin Endocrinol Metab. 90(12):6392–6395.
13.
GlantschnigHScottKHamptonRWeiNMcCrackenPNantermetPZhaoJZVitelliSHuangLHaytkoPet al. 2011. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther. 338(2):568–578.
14.
HanXLLiuMVoiseyARenYSKurimotoPGaoTTeferaLDechowPKeHZFengJQ. 2011. Post-natal effect of overexpressed DKK1 on mandibular molar formation. J Dent Res. 90(11):1312–1317.
15.
HanssonSHalldinA.2012. Alveolar ridge resorption after tooth extraction: a consequence of a fundamental principle of bone physiology. J Dent Biomech. 3:1758736012456543.
16.
HerfordASDeanJS. 2011. Complications in bone grafting. Oral Maxillofac Surg Clin North Am. 23(3):433–442.
17.
JagerAGotzWLossdorferSRath-DeschnerB.2010. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res. 45(2):246–254.
18.
JavedFAhmedHBCrespiRRomanosGE. 2013. Role of primary stability for successful osseointegration of dental implants: factors of influence and evaluation. Interv Med Appl Sci. 5(4):162–167.
19.
JeffcoatMK.1993. Bone loss in the oral cavity. J Bone Miner Res. 8Suppl 2:S467–S473.
20.
KeHZRichardsWGLiXOminskyMS. 2012. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 33(5):747–783.
21.
KimJHKimARChoiYHJangSWooGHChaJHBakEJYooYJ. 2017. Tumor necrosis factor-alpha antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis. PLoS One. 12(12):e0189702.
22.
KimJHLeeDEChaJHBakEJYooYJ. 2014. Receptor activator of nuclear factor-kappaB ligand and sclerostin expression in osteocytes of alveolar bone in rats with ligature-induced periodontitis. J Periodontol. 85(11):e370–e378.
23.
KostenuikPJShalhoubV.2001. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 7(8):613–635.
24.
KuchlerUSchwarzeUYDobsakTHeimelPBosshardtDDKneisselMGruberR.2014. Dental and periodontal phenotype in sclerostin knockout mice. Int J Oral Sci. 6(2):70–76.
25.
LiXGrisantiMFanWAsuncionFJTanHLDwyerDHanCYYuLLeeJLeeEet al. 2011. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 26(11):2610–2621.
26.
LiXOminskyMSWarmingtonKSMoronySGongJCaoJGaoYShalhoubVTiptonBHaldankarRet al. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 24(4):578–588.
27.
LinCJiangXDaiZGuoXWengTWangJLiYFengGGaoXHeL.2009. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 24(10):1651–1661.
28.
Lioubavina-HackNLangNPKarringT.2006. Significance of primary stability for osseointegration of dental implants. Clin Oral Implants Res. 17(3):244–250.
29.
McClungMRGrauerABoonenSBologneseMABrownJPDiez-PerezALangdahlBLReginsterJYZanchettaJRWassermanSMet al. 2014. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 370(5):412–420.
30.
MorvanFBoulukosKClement-LacroixPRoman RomanSSuc-RoyerIVayssiereBAmmannPMartinPPinhoSPognonecPet al. 2006. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 21(6):934–945.
31.
MoustafaASugiyamaTPrasadJZamanGGrossTSLanyonLEPriceJS. 2012. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int. 23(4):1225–1234.
32.
NapimogaMHNametalaCda SilvaFLMirandaTSBossonaroJPDemasiAPDuartePM. 2014. Involvement of the Wnt-beta-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol. 41(6):550–557.
33.
NishiyamaYMatsumotoTLeeJWSaitouTImamuraTMoriyamaKYamaguchiAIimuraT. 2015. Changes in the spatial distribution of sclerostin in the osteocytic lacuno-canalicular system in alveolar bone due to orthodontic forces, as detected on multimodal confocal fluorescence imaging analyses. Arch Oral Biol. 60(1):45–54.
34.
OminskyMSBoydSKVarelaAJoletteJFelxMDoyleNMellalNSmithSYLocherKBuntichSet al. 2017. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 32(4):788–801.
35.
OminskyMSBrownDLVanGCordoverDPachecoEFrazierECherepowLHiggins-GarnMAguirreJIWronskiTJet al. 2015. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone. 81:380–391.
36.
PagniGPellegriniGGiannobileWVRasperiniG.2012. Postextraction alveolar ridge preservation: biological basis and treatments. Int J Dent. 2012:151030.
37.
RenYHanXHoSPHarrisSECaoZEconomidesANQinCKeHLiuMFengJQ. 2015. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. Fed Am Soc Exp Biol J. 29(7):2702–2711.
38.
RoblingAGBellidoTTurnerCH. 2006. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact. 6(4):354.
39.
RoblingAGNiziolekPJBaldridgeLACondonKWAllenMRAlamIMantilaSMGluhak-HeinrichJBellidoTMHarrisSEet al. 2008. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 283(9):5866–5875.
40.
SennerbyLCarlssonGEBergmanBWarfvingeJ.1988. Mandibular bone resorption in patients treated with tissue-integrated prostheses and in complete-denture wearers. Acta Odontol Scand. 46(3):135–140.
41.
TanWLWongTLWongMCLangNP. 2012. A systematic review of post-extractional alveolar hard and soft tissue dimensional changes in humans. Clin Oral Implants Res. 23Suppl 5:1–21.
42.
TautADJinQChungJHGalindo-MorenoPYiESSugaiJVKeHZLiuMGiannobileWV. 2013. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 28(11):2347–2356.
43.
TaylorSOminskyMSHuRPachecoEHeYDBrownDLAguirreJIWronskiTJBuntichSAfshariCAet al. 2016. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone. 84:148–159.
44.
VirdiASIrishJSenaKLiuMKeHZMcNultyMASumnerDR. 2015. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis. J Bone Joint Surg Am. 97(2):133–140.
45.
WangFSKoJYLinCLWuHLKeHJTaiPJ. 2007. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss: a histomorphological study in ovariectomized rats. Bone. 40(2):485–492.
46.
WolffJ.1884. Das gesetz der transformation der inneren architektur der knochen bei pathologischen veranderungen äußeren knochenform. Sitz Ber Berliner Akad. 22(1884):475–496.
47.
XuYWangLSunYHanXGaoTXuXChenTZhaoXZengHWangYet al. 2016. Sclerostin is essential for alveolar bone loss in occlusal hypofunction. Exp Ther Med. 11(5):1812–1818.
48.
ZhangRHuangSWangLPengB.2014. Histochemical localization of Dickkopf-1 in induced rat periapical lesions. J Endod. 40(9):1394–1399.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
